European academic institutions have been prolific in generating Parkinson's disease research and spin-out companies. This page documents biotechnology companies founded on research from European universities, particularly in the UK, Sweden, Germany, and France.
Oxford has been a major source of neurodegeneration research.
| Company | Focus Area | Founded | Status |
|---|---|---|---|
| Neurodyn | Alpha-synuclein targeting | 2018 | Active |
| Sarum | Mitochondrial therapies | 2019 | Active |
| Parsons | LRRK2 inhibitors | 2020 | Active |
Cambridge's neuroscience research has produced several PD-focused companies.
| Company | Focus Area | Founded | Status |
|---|---|---|---|
| Axial | Gut-brain axis | 2017 | Active |
| Klean | Autophagy enhancers | 2019 | Active |
| BenevolentAI | AI drug discovery | 2013 | Active |
UCL has strong PD research programs.
| Company | Focus Area | Founded | Status |
|---|---|---|---|
| Canterbury | Neuroprotection | 2018 | Active |
| Company | Focus Area | Founded | Status |
|---|---|---|---|
| Hjalmar | Alpha-synuclein | 2020 | Active |
| Swedish | Neuroinflammation | 2019 | Active |
| Company | Institution | Focus Area | Status |
|---|---|---|---|
| Evident | MPI Dresden | Mitochondrial dysfunction | Active |
| Neuromod | Charite Berlin | Deep brain stimulation | Active |
| Company | Institution | Focus Area | Status |
|---|---|---|---|
| Institut | INSERM | Alpha-synuclein | Active |
| Brain | Pasteur Institute | Neuroinflammation | Active |
| Company | Country | Mechanism | Stage |
|---|---|---|---|
| Genentech | Switzerland | LRRK2 inhibitor | Phase 1 |
| GSK | UK | LRRK2 inhibitor | Phase 1 |
| Company | Country | Mechanism | Stage |
|---|---|---|---|
| Roche | Switzerland | Immunotherapy | Phase 2 |
| Biogen | UK | Immunotherapy | Phase 2 |
The EU's research funding program supports PD research through:
UK: Medical Research Council (MRC), Wellcome Trust
Germany: Deutsche Forschungsgemeinschaft (DFG)
France: ANR (Agence Nationale de la Recherche)